Formulation and Drug Delivery, Biologic Drugs

Optimizing the patient experience and technological advances can positively impact adherence.

The drug is approved in the United States specifically for treating acquired thrombotic thrombocytopenic purpura, a rare blood-clotting disorder.

To ensure the sterility of parenteral biopharmaceutical products, it is necessary to employ certain tools, technologies, and standard operating procedures.

As biologic drugs grow increasingly complex, drug delivery mechanisms such as prefilled syringes are being adapted to meet the challenges.

The drug particle engineering and nanotechnology company offers a nanotechnology platform that can revive failed drugs in the pharma pipeline.

The companies will collaborate to bring InnoCore Pharmaceuticals’ proprietary SynBiosys biodegradable polymer platform to market.

Biosimilars and biobetters have their own unique manufacturing strategies and challenges.

Single-use technologies have become increasingly prevalent in final fill/finish operations for biologics.

Catalent’s GPEx technology was used to develop antibody for anti-methamphetamine clinical study.

Aseptic fill/finish is crucial in biopharma manufacturing and is optimized through automated technology.

Transcriptomics plays a role in influencing the production of recombinant therapeutics in microbial and mammalian hosts.

Advances in wearable devices have made it possible to deliver high-volume, high-viscosity biologics.

Researchers at the University of Illinois developed a method to transplant pancreatic islet cells from pigs more easily to treat type I diabetes.

Conducting stability testing on APIs/finished drug product helps ensure shelf-life storage.

ADC Bio experts warn of impending problems in the ADC pipeline with millions wasted in development costs.

The authors of the study believe it could have significant implications for the discovery of new dermatological products for major diseases such as psoriasis.

Siliconization is a key process step in the manufacturing of prefilled syringe systems.

Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.

Gelest, a manufacturer and provider of silane, silicone, and metal-organic compounds, released a range of dual-function poly(ethylene glycol) (PEG) reagents that enable new approaches to PEGylation for bioconjugates.

There is a lot of interest in delivering biologics via non-invasive routes in attempt to improve patient compliance and convenience.

Microdermics will focus on product development and clinical activities of new drug delivery methods, while Vetter’s primary role will be in the fill and finish aspect.

Researchers test the efficacy of a new polymer that is an alternative to PEG for drugs used to treat type 2 diabetes.

The baculovirus-insect cell system can produce large quantities of complex protein in a short period of time.

Challenging molecules and markets are driving the development of new solutions for drug delivery.

A new study examines the oral delivery of protein drugs in plant cells and hypothesizes that the cold storage and transportation of biologics could someday be eliminated.